Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

First Page		Document Content
Date: 2016-08-04 23:27:20 Breakthrough therapy Chemistry Pharmaceutical sciences Carbamates Pharmacology Pyrrolidines Ombitasvir/paritaprevir/ritonavir Ritonavir Ombitasvir AbbVie Inc. Paritaprevir Kidney		Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio Add to Reading List Source URL: www.pmda.go.jp Download Document from Source Website File Size: 95,95 KB Share Document on Facebook

	January 31, 2013 Re: Information for Canadian resident shareholders concerning the Canadian Income Tax Election on the spin-off of AbbVie Inc. from Abbott Laboratories DocID: 1xW00 - View Document
	Le 31 janvierObjet : Information concernant le choix de report de l’impôt sur le revenu à l’intention des actionnaires résidant au Canada détenteurs d’actions d’AbbVie Inc. suivant la scission de Labor DocID: 1xVKk - View Document
	Laboratory Investigation, 970–982 & 2013 USCAP, Inc All rights reserved $32.00 PATHOBIOLOGY IN FOCUS Patient-derived xenografts, the cancer stem cell DocID: 1uW4K - View Document
	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1qWZQ - View Document
	Microsoft Word - Final Abbott_AbbVie Tax Basis Statement DocID: 1qPLH - View Document